lethargy; tiredness; unwell; neutropenia; this is a spontaneous report received from a contactable reporter(s) (consumer or other non hcp) from the regulatory authority. regulatory number: gb-mhra-webcovid-202202171255370010-wkk59. a 77 year-old female patient received bnt162b2 (bnt162b2), administration date 07jan2021 (lot number: elo141) as dose 1 , single for covid-19 immunisation. relevant medical history included: "surgery" (unspecified if ongoing), notes: had surgery to remove fibroid but found not to be the cause; "fibroid" (unspecified if ongoing), notes: had surgery to remove fibroid but found not to be the cause. concomitant medication(s) included: fluvax, administration date 01oct2021. the following information was reported: neutropenia (medically significant) with onset 01mar2021, outcome "recovering", described as "neutropenia"; lethargy (non-serious), outcome "recovering", described as "lethargy"; fatigue (non-serious), outcome "recovering", described as "tiredness"; malaise (non-serious), outcome "recovering", described as "unwell". the patient underwent the following laboratory tests and procedures: blood test: unknown results; magnetic resonance imaging: unknown results. therapeutic measures were taken as a result of neutropenia. clinical course: the patient began to feel unwell weeks after first dose. the patient experienced tiredness and lethargy. she was found to be neutropenic and needed iron transfusions. had surgery to remove fibroid but found not to be the cause. rash began after booster. all over body, severe itching, bleeding skin all over. currently being investigated. the patient has not tested positive for covid-19 since having the vaccine. the patient is not enrolled in clinical trial. no follow-up attempts are possible. no further information is expected

test name: blood tests; result unstructured data: test result:unknown results; test name: mri scan; result unstructured data: test result:unknown results

na

na